FindTrial
Sign In

To Study Serum Adiponectin As Biomarker For Insulin Resistance In Newly Diagnosed Type 2 Diabetes

Serum Adiponectin Levels as a Biomarker for Insulin Resistance in Newly Diagnosed Type 2 Diabetes Mellitus patients: A Cross-Sectional Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/104141
Enrollment
70
Registered
2026-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Manan Patel
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients of either sex with age more than 18 years willing to participate in the study, individuals with recent onset type 2 diabetes mellitus, hba1c levels more than 6.5

Exclusion criteria

Exclusion criteria: subjects on insulin therapy or oral hypoglycemic agents, subjects with chronic illnesses like Chronic kidney disease,heart failure or Chronic liver disease

Design outcomes

Primary

MeasureTime frame
To assess serum adiponectin levels in newly diagnosed type 2 Diabetes Mellitus patientsTimepoint: Serum adiponectin levels at the time of admission—

Secondary

MeasureTime frame
to correlate adiponectin levels with insulin resistance markers like HOMA-IR, fasting insulin & fasting glucose Timepoint: Fasting insulin levels at day 1 of admission Fasting glucose levels at day 1 of admission—

Countries

India

Contacts

Public ContactDr Manan Prakash Patel

Jawaharlal Nehru Medical College

arifmaldar@yahoo.com08312471350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026